NCPC(SH:600812) Mei Ri Jing Ji Xin Wen·2025-08-04 09:07Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]